Verastem, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Verastem, Inc. (VSTM) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Verastem, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.43M, a 0.50% increase year-over-year.
- Verastem, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.05M, a 14.43% increase year-over-year.
- Verastem, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.18M, a 12.56% increase year-over-year.
- Verastem, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.41M, a 79.16% increase year-over-year.
- Verastem, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $9.40M, a 28.08% increase from fiscal 2024.
- Verastem, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $7.34M, a 25.29% increase from fiscal 2023.
- Verastem, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $5.86M, a 3.09% decline from fiscal 2022.
- Verastem, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $6.05M, a 21.58% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 5 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.43M 10-Q · filed 2026-08-06 | $5.48M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $2.05M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $9.40M 10-K · filed 2026-03-04 | ||||
| 2025-09-30 | $2.18M 10-Q · filed 2025-11-04 | $5.59M derived: sum of 2 quarters · filed 2026-08-06 | $7.38M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $3.41M 10-Q · filed 2026-08-06 | $5.20M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $1.79M 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $7.34M 10-K · filed 2026-03-04 | ||||
| 2024-09-30 | $1.94M 10-Q · filed 2025-11-04 | $3.84M derived: sum of 2 quarters · filed 2025-11-04 | $5.32M derived: sum of 3 quarters · filed 2025-11-04 | ||
| 2024-06-30 | $1.91M 10-Q · filed 2025-11-04 | $3.39M derived: sum of 2 quarters · filed 2025-11-04 | |||
| 2024-03-31 | $1.48M 10-Q · filed 2025-11-04 | ||||
| 2023-12-31 | $5.86M 10-K · filed 2026-03-04 | ||||
| 2023-09-30 | $1.52M 10-Q · filed 2024-11-06 | $2.95M derived: sum of 2 quarters · filed 2024-11-06 | $4.26M derived: sum of 3 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $1.43M 10-Q · filed 2024-11-06 | $2.75M derived: sum of 2 quarters · filed 2024-11-06 | |||
| 2023-03-31 | $1.31M 10-Q · filed 2024-11-06 | ||||
| 2022-12-31 | $6.05M 10-K · filed 2025-03-20 | ||||
| 2022-09-30 | $1.36M 10-Q · filed 2023-11-08 | $3.11M derived: sum of 2 quarters · filed 2023-11-08 | $4.76M derived: sum of 3 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $1.76M 10-Q · filed 2023-11-08 | $3.40M derived: sum of 2 quarters · filed 2023-11-08 | |||
| 2022-03-31 | $1.65M 10-Q · filed 2023-11-08 | ||||
| 2021-12-31 | $7.71M 10-K · filed 2024-03-14 | ||||
| 2021-09-30 | $1.99M 10-Q · filed 2022-11-03 | $4.16M derived: sum of 2 quarters · filed 2022-11-03 | $6.14M derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $2.17M 10-Q · filed 2022-11-03 | $4.15M derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | $1.98M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $8.12M 10-K · filed 2023-03-14 | ||||
| 2020-09-30 | $2.16M 10-Q · filed 2021-11-04 | $3.81M derived: sum of 2 quarters · filed 2021-11-04 | $5.18M derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $1.66M 10-Q · filed 2021-11-04 | $3.03M derived: sum of 2 quarters · filed 2021-11-04 | |||
| 2020-03-31 | $1.37M 10-Q · filed 2021-11-04 | ||||
| 2019-12-31 | $8.54M 10-K · filed 2022-03-28 | ||||
| 2019-09-30 | $1.92M 10-Q · filed 2020-11-09 | $4.98M derived: sum of 2 quarters · filed 2020-11-09 | $7.23M derived: sum of 3 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $3.06M 10-Q · filed 2020-11-09 | $5.31M derived: sum of 2 quarters · filed 2020-11-09 | |||
| 2019-03-31 | $2.25M 10-Q · filed 2020-11-09 | ||||
| 2018-12-31 | $6.67M 10-K · filed 2021-03-18 | ||||
| 2018-09-30 | $2.04M 10-Q · filed 2019-10-30 | $3.58M derived: sum of 2 quarters · filed 2019-10-30 | $4.91M derived: sum of 3 quarters · filed 2019-10-30 | ||
| 2018-06-30 | $1.54M 10-Q · filed 2019-10-30 | $2.87M derived: sum of 2 quarters · filed 2019-10-30 | |||
| 2018-03-31 | $1.33M 10-Q · filed 2019-10-30 | ||||
| 2017-12-31 | $5.03M 10-K · filed 2020-03-11 | ||||
| 2016-12-31 | $6.29M 10-K · filed 2019-03-12 | ||||
| 2015-12-31 | $10.09M 10-K · filed 2018-03-13 | ||||
| 2014-12-31 | $12.36M 10-K · filed 2017-03-23 | ||||
| 2013-12-31 | $9.68M 10-K · filed 2016-03-03 | ||||
| 2012-12-31 | $7.40M 10-K · filed 2015-03-10 | ||||
| 2011-12-31 | $1.64M 10-K · filed 2014-03-06 | ||||
| 2010-12-31 | $52.00K 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |